Details
Stereochemistry | ACHIRAL |
Molecular Formula | C26H27ClN2O |
Molecular Weight | 418.958 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2)CC(=O)C4=CC=C(Cl)C=C4
InChI
InChIKey=SAPNXPWPAUFAJU-UHFFFAOYSA-N
InChI=1S/C26H27ClN2O/c1-28(19-26(30)22-13-15-23(27)16-14-22)17-6-18-29-24-9-4-2-7-20(24)11-12-21-8-3-5-10-25(21)29/h2-5,7-10,13-16H,6,11-12,17-19H2,1H3
Molecular Formula | C26H27ClN2O |
Molecular Weight | 418.958 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Lofepramine is a tricyclic antidepressant that is structurally similar to imipramine and is extensively metabolised to desipramine. In the absence of other major pharmacological effects it appears that its antidepressant activity stems from the facilitation of noradrenergic neurotransmission by uptake inhibition, and possibly by the additional facilitation of serotoninergic neurotransmission. The overall therapeutic efficacy of lofepramine is comparable to that of imipramine, amitriptyline, clomipramine, maprotiline and mianserin in patients with depression of varying severity, and coexisting anxiety. Lofepramine is a strong inhibitor of norepinephrine reuptake (Ki=5.4 nM) and a moderate inhibitor of serotonin reuptake (Ki=70 nM). It is a weak-intermediate level antagonist of the muscarinic acetylcholine receptors.Lofepramine is licensed for the treatment of depression in the United Kingdom.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
4.5 nM [IC50] | |||
Target ID: CHEMBL228 |
7.15 null [pKi] | ||
Target ID: CHEMBL222 |
8.27 null [pKi] | ||
Target ID: CHEMBL2094109 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3094050 |
285.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Lofepramine Approved UseLofepramine Tablets are used to treat the symptoms
of depression. Common symptoms include feelings of
worthlessness or deep sadness, difficulty with everyday
tasks, sleeping too much or not being able to sleep, and
feeling anxious. |
PubMed
Title | Date | PubMed |
---|---|---|
Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. | 1999 Aug |
|
Meta-analytical studies on new antidepressants. | 2001 |
|
MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine. | 2001 Jul 3 |
|
Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care. | 2001 Sep 22 |
|
Managing MS. While a cure is sought, people with MS can help themselves. | 2002 Nov |
|
Nonpharmacological treatments for anxiety disorders. | 2002 Sep |
|
Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. | 2004 |
|
Risk of fetal exposure to tricyclic antidepressants. | 2004 Oct |
|
Solid-phase extraction and analysis of 20 antidepressant drugs in human plasma by LC/MS with SSI method. | 2006 Oct 16 |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
Tricyclic antidepressants and headaches: systematic review and meta-analysis. | 2010 Oct 20 |
Sample Use Guides
The recommended dose for adults is one tablet to
be taken 2 or 3 times a day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3094050
The mean value for the inhibition constant (Ki) for lofepramine in human parotid gland was 285 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:53:32 UTC 2023
by
admin
on
Sat Dec 16 17:53:32 UTC 2023
|
Record UNII |
OCA4JT7PAW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN06AA07
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
||
|
WHO-ATC |
N06AA07
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
||
|
NCI_THESAURUS |
C265
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB08557MIG
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
100000082000
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
1592
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
245-396-8
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
CHEMBL87708
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
7184
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
LOFEPRAMINE
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
47782
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
OCA4JT7PAW
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
2909
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
DB13411
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
23047-25-8
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
7551
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
D008127
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
6465
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | RxNorm | ||
|
3947
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
m6884
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | Merck Index | ||
|
C87615
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY | |||
|
DTXSID2023220
Created by
admin on Sat Dec 16 17:53:32 UTC 2023 , Edited by admin on Sat Dec 16 17:53:32 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |